Cargando…

Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia

The prognosis of cytogenetically normal acute myeloid leukemia (CN-AML) varies greatly among patients. Achievement of complete remission (CR) after chemotherapy is indispensable for a better prognosis. To develop a gene signature predicting overall survival (OS) in CN-AML, we performed data mining p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Han, Wen, Lu, Tan, Dan, Xie, Pan, Pang, Feng-mei, Zhou, Hong-hao, Zhang, Wei, Liu, Zhao-qian, Tang, Jie, Li, Xi, Chen, Xiao-ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352074/ https://www.ncbi.nlm.nih.gov/pubmed/27903973 http://dx.doi.org/10.18632/oncotarget.13650

Ejemplares similares

Pharmacometabolomics identifies dodecanamide and leukotriene B4 dimethylamide as a predictor of chemosensitivity for patients with acute myeloid leukemia treated with cytarabine and anthracycline
por: Tan, Guangguo, et al.
Publicado: (2017)

Prognostic role of ACTL10 in Cytogenetic Normal Acute Myeloid Leukemia
por: Lai, Rui, et al.
Publicado: (2020)

Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia
por: Wang, Mengning, et al.
Publicado: (2017)

DNA sequencing of a cytogenetically normal acute myeloid leukemia genome
por: Ley, Timothy J, et al.
Publicado: (2008)

Altered expression of imprinted genes in patients with cytogenetically normal‑acute myeloid leukemia: Implications for leukemogenesis and survival outcomes
por: Yang, Ming-Yu, et al.
Publicado: (2023)

The Prognostic Significance of PDE7B in Cytogenetically Normal Acute Myeloid Leukemia
por: Cao, Ling, et al.
Publicado: (2019)

Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
por: Tabe, Yoko, et al.
Publicado: (2018)

A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia
por: Zhu, Ruiqi, et al.
Publicado: (2017)

Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics
por: Gregory, Tara K, et al.
Publicado: (2009)

Acute promyelocytic leukemia relapsing into acute myeloid leukemia-M2 with normal cytogenetics
por: Sahoo, Ranjit Kumar, et al.
Publicado: (2013)

KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia
por: Zhou, Jing-Dong, et al.
Publicado: (2017)

The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study
por: Chen, Guofeng, et al.
Publicado: (2022)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia
por: Song, Ying, et al.
Publicado: (2019)

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
por: Momparler, Richard L
Publicado: (2013)

Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study
por: Ye, Li, et al.
Publicado: (2021)

TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia
por: Qian, Sixuan, et al.
Publicado: (2016)

High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts
por: Wang, Jinghan, et al.
Publicado: (2018)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance
por: Åbacka, Hannah, et al.
Publicado: (2021)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
por: Leonard, Sarah M., et al.
Publicado: (2014)

Wilms Tumor 1 Gene Mutations in Patients with Cytogenetically Normal Acute Myeloid Leukemia
por: Aref, Salah, et al.
Publicado: (2014)

Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults
por: Tsui, Sze P., et al.
Publicado: (2020)

Cytogenetics’ impact on the prognosis of acute myeloid leukemia
por: Gupta, Monika, et al.
Publicado: (2019)

Cytogenetic characteristics of and prognosis for acute myeloid leukemia in 107 children
por: Chen, Wanzi, et al.
Publicado: (2021)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia
por: Fu, Lin, et al.
Publicado: (2016)

Aberrant Chloride Intracellular Channel 4 Expression Is Associated With Adverse Outcome in Cytogenetically Normal Acute Myeloid Leukemia
por: Huang, Sai, et al.
Publicado: (2020)

DNA Methylation Signatures Predict Cytogenetic Subtype and Outcome in Pediatric Acute Myeloid Leukemia (AML)
por: Krali, Olga, et al.
Publicado: (2021)

Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
por: Bashir, Yasir, et al.
Publicado: (2015)

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells
por: Li, Peng, et al.
Publicado: (2016)

Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
por: Liu, Junmin, et al.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia
por: Sun, Huali, et al.
Publicado: (2023)

Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics
por: Fernandez-Mercado, Marta, et al.
Publicado: (2012)

Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients
por: Bou Samra, Elias, et al.
Publicado: (2012)

High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia
por: Fu, Lin, et al.
Publicado: (2016)

Prognostic Prediction of Cytogenetically Normal Acute Myeloid Leukemia Based on a Gene Expression Model
por: Yang, Liu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eqng8gunlrjggo1anfdlq4l91d